Monoclonal antibody therapy of human gliomas: Current status and future approaches

Cancer and Metastasis Reviews

Volumn 18, Issue 4, 1999, Pages 451-464

  Wikstrand, Carol J ^a   Cokgor, Ilkcan ^a   Sampson, John H ^a   Bigner, Darell D ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Gliomas; Immunotherapy; Mab constructs; Mab2; Medulloblastoma

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 425; MONOCLONAL ANTIBODY BC 2; MONOCLONAL ANTIBODY BC 4; TENASCIN; TENASCIN ANTIBODY; UNCLASSIFIED DRUG;

ANTIGEN RECOGNITION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CLINICAL TRIAL; DRUG EFFICACY; DRUG TARGETING; GLIOMA; HUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; BRAIN NEOPLASMS; GLIOMA; HUMANS; IMMUNOTHERAPY; PROTEIN ENGINEERING; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 0033512319     PISSN: 01677659     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006354102377     Document Type: Article

References (80)

1. 1. Ehrlich P: Collected Studies on Immunity. Wiley, New York, 1906
2. 2. Wikstrand CJ, Zalutsky MR, Bigner DD: Therapy of brain tumors with radiolabeled antibodies. In: Liau LM, Bigner DD (eds) Brain Tumor Immunotherapy, Humana Press (in press), 2000
3. 3. Kohler G, Milstein C: Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256: 495-497, 1975
4. 4. Carlsson J, Gedda L, Gronvik C, Hartman T, Lindstrom A, Lindstrom P, Lundqvist H, Lovqvist A, Malmqvist J, Olsson P, Essand M, Ponten J, Sjoberg S, Westermark B: Strategy for boron neutron capture therapy against tumor cells with overexpression of the epidermal growth factor receptor. Int J Radiat Oncol Biol Phys 30: 105-115, 1994
5. 5. Wikstrand CJ, McLendon RE, Friedman AH, Bigner DD: Cell surface localization and density of the tumor-associated variant of the epidermal growth factor receptor, EGFRvIII. Cancer Res 57: 4130-4140, 1997
6. 6. Mahaley Jr MS, Mahaley JL, Day ED: The localization of radioantibodies in human brain tumors. II. Radioautography. Cancer Res 25: 779-793, 1965
7. 131monoclonal antibodies in treating neural tumors. In: Vaeth IM, Meuer JL (eds) The Present and Future Role of Monoclonal Antibodies in the Management of Cancer. Front Radiat Ther Oncol 24: 166-181, 1990
8. 2 - A preliminary report. J Neurooncol 24: 109-122, 1995
9. 2 monoclonal antibody (MAb) treatment of patients with brain tumors (BT) and leptomeningeal metastases (LM). J Neurooncol 28: 66, 1996
10. 131I: comparison of the results obtained in recurrent and newly diagnosed tumors. Cancer Res (Suppl) 55: 5952s-5956s, 1995
11. 11. Kalofono HP, Pawlikowska TR, Hemingway A, Courtenay-Luck N, Dhokia B, Snook D, Sivolapenko GB, Hooker GR, McKenzie CG, Lavender PJ, Thomas DGT, Epenetos AA: Antibody guided diagnosis and therapy of brain gliomas using radiolabeled monoclonal antibodies against epidermal growth factor receptor and placental alkaline phosphatase. J Nucl Med 30: 1636-1645, 1989
12. 12. Brady LW, Miyamoto C, Woo DV, Rackover PA-C, Emrich J, Bender H, Dadparvar S, Steplewski Z, Koprowski H, Black P, Lazzaro B, Nair S, McCormack T, Nieves J, Morabito M, Eshleman J: Malignant astrocytomas treated with iodine-125 labeled monoclonal antibody 425 against epidermal growth factor receptor: a phase II trial. J Rad Oncol Biol Phys 22: 225-230, 1992
13. 13. Gillespie Y: History of brain tumor immunotherapy (Immunotherapeutic approaches for brain tumors - 30 years out and counting). In: Liau LM, Bigner DD (eds) Brain Tumor Immunotherapy. Humana Press (in press), 2000
14. 14. Zalutsky MR: Radionuclide therapy, a review. In: Amaldi U, Larsson B (eds) Hadrontherapy in Oncology. Elsevier Science, Amsterdam, 1994, pp 664-676
15. 15. Zalutsky MR, Schuster JM, Garg PK, Archer Jr GE, Dewhirst MW, Bigner DD: Two approaches for enhancing radioimmunotherapy: Alpha emitters and hyperthermia. Recent Results Cancer Res 141: 101-121, 1996
16. 16. Ventimiglia JB, Wikstrand CJ, Ostrowski LE, Bourdon MA, Lightner VA, Bigner DD: Tenascin expression in human glioma lines and normal tissues. J Immunol 36: 41-55, 1992
17. 17. Wikstrand CJ, Fung K-M, Trojanowski JQ, McLendon RE, Bigner DD: Antibodies and molecular immunology: Immunohistochemistry and antigens of diagnostic significance. Chapter 8 in: Bigner DD, McLendon RE, Bruner JM (eds) Russell and Rubinstein's Pathology of the Nervous System, 6th edn). Oxford University Press, New York, 1998, pp 251-304
18. 18. Carnemolla B, Castellani P, Ponassi M, Borsi L, Urbini S, Nicolo G, Dorcaratto A, Viale G, Winter G, Neri D, Zardi L. Identification of a glioblastoma-associated tenascin-C isoform by a high affinity recombinant antibody. Amer J Pathol 154: 1345-52, 1999
19. 19. Murphy-Ullrich JE, Lightner VA, Aukhil I, Yan YZ, Erickson HP, Höök M: Focal adhesion integrity is down-regulated by the alternatively spliced domain of human tenascin. J Cell Biol 115: 1127-1136, 1991
20. 20. Wikstrand CJ, Reist CJ, Archer GE, Zalutsky MR, Bigner DD: The class III variant of the epidermal growth factor receptor (EGFRvIII): characterization and utilization as an immunotherapeutic target. J Neuro Virol 4: 148-158, 1998
21. 21. Waterfield MD, Mayes ELV, Stroobant P, Bennet PLP, Young S, Goodfellow PN, Banting GS, Ozanne B: A monoclonal antibody to the human epidermal growth factor receptor. J Cell Biochem 20: 149-161, 1982
22. 22. Murthy U, Basu A, Rodeck U, Herlyn M, Ross AH, Das M : Binding of an antagonistic monoclonal antibody to an intact and fragmented EGF-receptor polypeptide. Arch Biochem Biophys 252: 549-560, 1987
23. 23. Wikstrand CJ, Hale LP, Batra SK, Hill ML, Humphrey PA, Kurpad SN, McLendon RE, Moscatello D, Pegram CN, Reist CJ, Traweek ST, Wong AJ, Zalutsky MR, Bigner DD: Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. Cancer Res 55: 3140-3148, 1995
24. 125I-labeled anti-EGFRvIII single-chain Fv exhibits specific and high-level targeting of xenografts. Clin Cancer Res 5: 1539-1549, 1999
25. 25. Lorimer IAJ, Keppler-Hafkemeyer A, Beers RA, Bigner DD, Pastan II: Recombinant immunotoxins specific for mutant epidermal growth factor receptor: targeting with a single chain Fv isolated by phage display. Proc Natl Acad Sci USA 93: 14815-14820, 1996
26. 26. Reist CJ, Batra SK, Pegram CN, Bigner DD, Zalutsky MR: In vitro and in vivo behavior of radiolabeled chimeric anti-EGFRvIII monoclonal antibody: comparison with its murine parent. Nucl Med Biol 24: 637-647, 1997
27. 27. Shawler DL, Bartholomew R, Smith L, Dillman R: Human immune response to multiple injections of murine monoclonal IgG. J Immunol 135: 1530-1535, 1985
28. 28. Herlyn D, Somasumdaram R, Li W, Maruyama H: Antiidiotype cancer vaccines: past and future. Cancer Immunol Immunother 43: 65-78, 1996
29. 131I-chimeric mouse/human B72.3 monoclonal antibody in humans. Cancer Res 51: 5461-5466, 1991
30. 30. Adams GP, Schier R, Marshall K, Wolf EJ, McCall AM, Marks JD, Weiner LM: Increased affinity leads to improved selective tumor delivery of single-chain Fv antibodies. Cancer Res 58: 485-490, 1998
31. 31. Begent RHJ, Verhaar MJ, Chester KA, Casey JL, Green AJ, Napier MP, Hope-Stone LD, Cuhen H, Keep PA, Johnson OJ, Hawkins RE, Hilson AJW, Robson L: Clinical evidence of efficient tumor targeting based on single-chain Fv antibody selected from a combinatorial library. Nat Med 2: 979-984, 1996
32. 32. Colcher D, Pavlinkova G, Beresford G, Booth BJM, Choudhury A, Batra SK: Pharmacokinetics and biodistribution of genetically-engineered antibodies. Q J Nucl Med 42: 225-241, 1998
33. 33. Cokgor I, Akabani G, Kuan C-T, Friedman HS, Friedman AH, Coleman RE, McLendon RE, Bigner SH, Zhao X-G, Garcia-Turner A, Pegram CN, Wikstrand CJ, Herndon JE, Provenzale JM, Zalutsky MR, Bigner DD: Phase I trial results of Iodine-131-labeled anti-tenascin monoclonal antibody 81C6 treatment of patients with newly diagnosed malignant gliomas. Submitted, 2000
34. 34. Miyamoto CT, Brady LW, Rackover MA, Emrich J, Class R, Bender H, Micaily B, Steplewski Z: The use of epidermal growth factor receptor-425 monoclonal antibodies radiolabeled with Iodine-125 in the adjuvant treatment of patients with high grade gliomas of the brain. Recent Res Cancer Res 141: 183-192, 1996
35. 35. Moseley RP, Papanastassiou V, Zalutsky MR, Ashpole RD, Evans S, Bigner DD, Kemshead JT: Immunoreactivity, pharmacokinetics and bone marrow dosimetry of intrathecal radioimmunoconjugates. Int J Cancer 52: 38-43, 1992
36. 131I-labeled antitenascin monoclonal antibody 81C6 treatment of patients with leptomeningeal neoplasms or primary brain tumor resection cavities with subarachnoid communication: Phase I trial results. Clin Cancer Res 2: 963-972, 1996
37. 37. Riva P, Arista A, Tison V, Sturiale C, Franceschi G, Spinelli A, Rivan N, Casi M, Moscatelli G, Frattarelli M: Intralesional radioimmunotherapy of malignant gliomas. Cancer 73: 1076-1082, 1994
38. 131I-labeled monoclonal antibody therapy in patients with recurrent high grade gliomas. J Neuro-Oncol 21: 69, 1994
39. 39. Jain RK, Baxter LT: Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: significance of elevated interstitial pressure. Cancer Res 48: 7022-7032, 1988
40. 40. Riva P, Franceschi G, Arista A, Frattarelli M, Riva N, Cremonini AM, Giuliani G, Casi M: Local application of radiolabeled monoclonal antibodies in the treatment of high grade malignant gliomas. Cancer Suppl 80: 2733-2742, 1997
41. 41. Bigner DD, Brown MT, Friedman AH, Coleman RE, Akabani G, Friedman HS, Thorstad WL, McLendon RE, Bigner SH, Zhao X-G, Pegram CN, Wikstrand CJ, Herndon II JE, Vick NA, Paleologos N, Cokgor I, Provenzale JM, Zalutsky MR: Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: Phase I trial results. J Clin Oncol 16: 2202-2212, 1998
42. 131I-labeled anti-tenascin monoclonal antibody 81C6 via surgically created resection cavities. Neurology 50: A354, 1998
43. 43. Akabani G, Reist CJ, Cokgor I, Friedman AH, Friedman HS, Coleman E, Zhao X-G, Bigner DD, Zalutsky MR: Dosimetry of I-131 labeled 81C6 monoclonal antibody administered into surgically created resection cavities in malignant brain tumor patients. J Nucl Med (in press), 2000
44. 131I-labeled anti-tenascin monoclonal antibody. Radiology 209(P): 204, 1998
45. 45. Frost G, Patel K, Bourne S, Coakham HB, Kemshead JT: Expression of alternative isoforms of the neural cell adhesion molecule (NCAM) on normal brain and a variety of brain tumours. Neuropathol Appl Neurobiol 17: 207-217, 1991
46. 46. Velculescu VE, Zhang L, Vogelstein B, Kinzler K: Serial analysis of gene expression. Science 270: 484-487, 1995
47. 47. Zhang L, Zhou W, Velculescu VE, Kern SE, Hruban RH, Hamilton SR, Vogelstein B, Kinzler KW: Gene expression profiles in normal and cancer cells. Science 276: 1268-1272, 1997
48. 48. Hills D, Rowlinson-Busza G, Gullick WJ: Specific targeting of a mutant, activated EGF receptor found in glioblastoma using a monoclonal antibody. Int J Cancer 63: 537-543, 1995
49. 49. Okamoto S, Yoshikawa K, Obata Y, Shibuya M, Aoki S, Yoshida J, Takahashi T: Monoclonal antibody against the fusion junction of a deletion-mutant epidermal growth factor receptor. Br J Cancer 73: 1366-1372, 1996
50. 50. Moscatello DK, Ramirez G, Wong AJ: A naturally occurring mutant human epidermal growth factor receptor as a target for peptide vaccine immunotherapy of tumors. Cancer Res 57: 1419-1424, 1997
51. 51. Sampson JH, Crotty LE, Archer GE, Friedman AH, Friedman HS, Bigner DD: An EGFRvIII-specific peplide vaccine generates antitumor immunity through a humoral pathway. Abstract, Neuro-Oncology 1: S103, 1999
52. 52. Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, Restifo NP, Dudley ME, Schwarz SL, Spiess PJ, Wunderlich JR, Parkhurst MR, Kawakami Y, Seippk CA, Einhorn JH, White DE: Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 4: 321-327, 1998
53. 53. Fernandez N, Duffour MT, Perricaudet M, Lotze MT, Tursz T, Zitvogel L: Active specific T-cell-based immunotherapy for cancer: nucleic acids, peptides, whole native proteins, recombinant viruses, with dendritic cell adjuvants or whole tumor cell-based vaccines. Principles and future prospects. Cytokines Cell Mol Ther 4: 53-65, 1998
54. 54. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G, Schadendorf D: Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendrtic cells. Nat Med 4: 328-332, 1998
55. 55. Tjoa BA, Simmons SJ, Elgamal A, Rogers M, Ragde H, Kenny GM, Troycak MJ, Boyunton AL, Murphy JGP: Follow-up evaluation of a phase II prostate cancer vaccine trial. Prostate 40: 125-129, 1999
56. 56. Holtl L, Rieser C, Papesh C, Ramoner R, Rartsch G, Thurnher M: CD83+ blood dendritic cells as a vaccine for immunotherapy of metastatic renal-cell cancer. Lancet 352: 9137-9138, 1998
57. 57. Ashley DM, Faiola B, Nair S, Hale LP, Bigner DD, Gilboa E: Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors. J Exp Med 186: 1177-1182, 1997
58. 58. Archer GE, Heimberger AB, Villavicencio A, Friedman A, Friedman HS, Bigner DD, Sampson JH: In vitro generation of dendritic cells from the peripheral blood of patients with malignant gliomas for antigen specific immunotherapy. Abstract, Neuro-Oncology 1: S104, 1999
59. 59. Jerne NK: Towards a network theory of the immune system. Ann Immunol 125: 373, 1974
60. 60. Bowen R, Bona C: Stimulation of lymphocytic clones by anti-idiotypic antibodies: Basis for development of idiotypic vaccines. Prog Vaccinol 3: 8-21, 1991
61. 61. Herlyn D, Somasundaram R, Jacob L, Li W, Zaloudik J, Maruyama H, Benden A, Harris D, Mastrangelo M: Anti-idiotypic antibodies that mimic the colorectal cancer antigen C017-1A/GA733; twelve years of pre-clinical and clinical studies. In: Schoenfeld Y, Kennedy RC, Ferrone S (eds) Idiotypes in Medicine: Autoimmunity, Infection and Cancer. Elsevier Science, 1997, pp 477-489
62. 62. Schultes BC, Baum RP, Niesen IA, Noujaim AA, Madiyalakan R: Anti-idiotype induction therapy: anti-CA125 antibodies (Ab3) mediated tumor killing in patients treated with Ovarex Mab B43.13 (Ab1). Cancer Immunol Immunother 46: 210-212, 1998
63. 63. Wikstrand CJ, Cole VR, Crotty LE, Sampson JH, Bigner DD: Anti-idiotype monoclonal antibody (Mab) vaccine approach to the therapy of variant epidermal growth factor receptor (EGFRvIII)-expressing tumors. Abstract, Neuro-Oncology 1: S99, 1999
64. 64. Brait M, Tassignon J, Ismaili J, Marvel J, Meek K, Leo O, Urbain J: Some thoughts on the future of idiotypic vaccines. Prog Vaccinol 3: 1-7, 1991
65. 65. Wikstrand CJ, Longee DC, McLendon RE, Fuller GN, Friedman HS, Fredman P, Svennerholm L, Bigner DD: Lacatoatetraose series ganglioside 3′,6-isoLD1 in tumors of central nervous and other systems in vitro and in vivo. Cancer Res 53: 120-126, 1993
66. 66. Stein K: Anti-idiotypic vaccines for carbohydrate antigens. Prog. Vaccinol 3: 31-41, 1991
67. 67. Jinnohara T, Tsujisaki M, Saaki S, Hinoda Y, Taniguchi M, Imai K: Anti-tumor effect of internal image bearing anti-idiotypic monoclonal antibody in relation to GM3 ganglioside. Int J Cancer 76: 345-353, 1998
68. 68. McCaffery M, Yao T-J, Williams L, Livingston PO, Houghton AN, Chapman PB: Immunization of melanoma patients with BEC2 anti-idiotypic monoclonal antibody that mimics GD3 ganglioside: enhanced immunogenicity when combined with adjuvant. Clin Cancer Res 2: 679-686, 1996
69. 69. Sampson JH, Crotty LE, Lee S, Archer GE, Ashley DM, Wikstrand CJ, Small C, Dranoff G, Friedman AH, Friedman HS, Bigner DD: Unarmed, tumor-specific, monoclonal antibody effectively treats brain tumors through antibody-dependent macrophage-mediated cytotoxicity. Neuro-Oncology 1: S98, 1999
70. 70. Yang XD, Jia SC, Corvalan JR, Wang P, Davis CG, Jakobovits A: Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy. Cancer Res 59: 1236-1243, 1999
71. 71. Lonberg N, Taylor LD, Harding FA, Trounstine M, Higgins KMK, Schramm SR, Kuo C-C, Mashayekh R, Wymore K, McCabe UJG, Munoz-O'Regan D, O'Donnell SL, Lapachet ESG, Bengoechea T, Fishwild DM, Carmack CE, Kay RM, Huszar D: Antigen-specific human antibodies from mice comprising four distinct genetic modifications. Nature 368: 856-859, 1994
72. 72. Fishwild DM, O'Donnell SL, Bengoechea T, Hudson DV, Harding F, Bernhard SL, Jones D, Kay RM, Higgins KM, Schramm SR, Lonberg N: High-avidity human IgGk monoclonal antibodies from a novel strain of minilocus transgenic mice. Nat Biotech 14: 845-851, 1996
73. 73. Adams GPI, McCartney JE, Tai MS, Oppermann H, Huston JS, Stafford WF, Bookman MA, Fand I, Houston LL, Weiner LM: Highly specific in vivo tumor targeting by monovalent and divalent forms of 741F8 anti-c-erbB-2 single-chain Fv. Cancer Res 53: 4026-4034, 1993
74. 74. Beresford GW, Pavlinkova G, Booth BJM, Batra SK, Colcher D: Binding characteristics and tumor targeting of a covalently linked divalent CC49 single-chain antibody. Int J Cancer 81: 911-917, 1999
75. 75. Wu AM, Chen W, Raubitschek A, Williams LE, Neumaier M, Fischer R, Hu SZ, Odom MT, Wong JY, Shively JE: Improved targeting by non-covalent dimers. Immunotechnology 2: 21-36, 1996
76. 76. Archer GE, Sampson JH, Lorimer IAJ, McLendon RE, Kuan C-T, Friedman AH, Friedman HS, Pastan IH, Bigner DD: Regional treatment of EGFRvIII-expressing neoplastic meningitis with a single chain immunotoxin, MR-1. Clin Cancer Res 5: 2646-52, 1999
77. 77. Wikstrand CJ, Loney T, McLendon EE, Bigner DD: Characterization of a medulloblastoma-distinctive monoclonal antibody (Mab). Neuro-Oncology 1: S63-S64, 1999
78. 78. Zalutsky MR, Akabani G, Cokgor I, Friedman HS, Coleman RE, Friedman AH, McLendon RE, Reist CJ, Pegram CN, Zhao X-G, Bigner DD: Phase I trial of astatine-211 labeled human/mouse chimeric anti-tenascin antibody administered into malignant brain tumor resection cavities. Neuro-Oncology 1 Abstract issue, S65, 1999
79. 79. Dark GG, Hill SA, Price VE, Tozer GM, Pettit GR, Chaplin DJ: Combretastatain A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res 57: 1829-1834, 1997
80. 80. Pedley RB, Sharma SK, Boxer G, Boden R, Stribbling SM, Davies L, Springer CJ, Begent RHJ: Enhancement of antibody-directed enzyme prodrug therapy in colorectal xenografts by an antivascular agent. Cancer Res 59: 3998-4003, 1999